Quick Search


 

Protocol Summaries: maraviroc

ViiV
Study ID
   Phase    Title Status
115647 phase 4 A multicentre observational study to evaluate the effectiveness, safety and treatment costs of maraviroc used with optimized background therapy in treatment-experienced HIV infected patients in routine clinical practice in Portugal Completed
116278 phase 4 An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
116483 n\a Protocol to evaluate the public health value of maraviroc using the French hospital databaseon HIV infection (FHDH) Recruiting
A4001026 phase 3 A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects Completed
A4001031 Phase 2 An Open-label, Multicenter, Multiple-dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-experienced Ccr5-tropic Hiv-1 Infected Children 2 - <18 Years Of Age Recruiting
A4001067 phase 4 An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients Recruiting
A4001093 phase 4 Drug Use Investigation For HIV Infection Patients Of Maraviroc (Regulatory Post Marketing Commitment Plan) Active not recruiting
A4001095 Phase 3 A MULTICENTER, RANDOMIZED, DOUBLE‑BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL‑NAIVE HIV‑INFECTED PATIENTS WITH CCR5‑TROPIC HIV‑1 Recruiting
A4001098 Phase 4 A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED SUBJECTS CO-INFECTED WITH HEPATITIS C AND/OR HEPATITIS B VIRUS Active not recruiting
A4001101 Phase 4 A Multicenter, Open-label Study of Maraviroc, Zidovudine and Lamivudine Twice Daily for the Treatment of Antiretroviral Naïve HIV-Infected Patients with R5 HIV-1 in Russia Completed
A4001105 Phase 2 SELECTED CLINICAL EVENTS AMONG HIV-INFECTED AND HIV UNINFECTED PERSONS ENROLLED IN KAISER PERMANENTE Enrolling by invitation
A4001106 phase 4 Clinical Adverse Events In HIV-Infected Patients Enrolling by invitation